Skye Bioscience (SKYE) Accounts Payables (2012 - 2026)
Skye Bioscience (SKYE) posted quarterly Accounts Payables of $3.9 million for Q1 2026, up 129.72% year-over-year from $1.7 million in Q1 2025, and up 93.61% quarter-over-quarter from $2.0 million in Q4 2025.
Skye Bioscience (SKYE) Accounts Payables (2012 - 2026) Analysis & Trends
Skye Bioscience (SKYE) has reported Accounts Payables for 15 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables rose 129.72% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 129.72% YoY), while the FY2025 annual figure was $2.0 million, up 257.21% from the prior year.
- Accounts Payables grew to $3.9 million in Q1 2026 per SKYE's latest filing, from $2.0 million in the prior quarter.
- Across five years, Accounts Payables topped out at $3.9 million in Q1 2026 and bottomed at $47001.0 in Q4 2022.
- Historically, Accounts Payables has averaged $1.6 million across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2022 — Accounts Payables tumbled 94.77% — and 2023, when it surged 1935.6%.
- Skye Bioscience's Accounts Payables stood at $47001.0 in 2022, then soared by 1935.6% to $956754.0 in 2023, then tumbled by 40.5% to $569252.0 in 2024, then soared by 257.21% to $2.0 million in 2025, then jumped by 93.61% to $3.9 million in 2026.
- Business Quant data shows SKYE's Accounts Payables at $3.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 35.57 Mn |
| 10 | Skye Bioscience | 10.67 Mn | 10.67 Mn | - | 4.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.94 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 3.22 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 569,252.00 |
| Sep 30, 2024 | 780,025.00 |
| Jun 30, 2024 | 1.08 Mn |
| Mar 31, 2024 | 1.10 Mn |
| Dec 31, 2023 | 956,754.00 |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Mar 31, 2023 | 1.22 Mn |
| Dec 31, 2022 | 47,001.00 |
| Sep 30, 2022 | 2.07 Mn |
| Jun 30, 2022 | 1.44 Mn |
| Mar 31, 2022 | 878,720.00 |
| Dec 31, 2021 | 897,880.00 |
| Sep 30, 2021 | 318,982.00 |
| Jun 30, 2021 | 382,139.00 |